Posted by Michael Wonder on 08 Oct 2021
Health Canada approves the use of Rinvoq (upadacitinib) for the treatment of adults and adolescents with moderate to severe atopic dermatitis
7 October 2021 - Authorization is based on the results from three Phase 3 multicenter, randomized, double-blind, placebo-controlled registrational clinical trials evaluating the efficacy and safety or Rinvoq (upadacitinib) in monotherapy or in combination with topical corticosteroids.
AbbVie today announced that Health Canada has approved Rinvoq (upadacitinib), an oral, once daily selective JAK inhibitor for the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. Rinvoq can be used with or without topical corticosteroids.
